Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
:XERS
Total Valuation
Xeris Pharmaceuticals has a market cap or net worth of $704.68M. The enterprise value is $943.82M.
Market Cap$704.68M
Enterprise Value$943.82M
Share Statistics
Xeris Pharmaceuticals has 160,155,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding160,155,000
Owned by Insiders5.99%
Owned by Institutions9.74%
Financial Efficiency
Xeris Pharmaceuticals’s return on equity (ROE) is 1.85 and return on invested capital (ROIC) is -12.93%.
Return on Equity (ROE)1.85
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-12.93%
Return on Capital Employed (ROCE)-0.15
Revenue Per Employee515.41K
Profits Per Employee-139.18K
Employee Count394
Asset Turnover0.63
Inventory Turnover0.76
Valuation Ratios
The current PE Ratio of Xeris Pharmaceuticals is -9.07. Xeris Pharmaceuticals’s PEG ratio is -0.74.
PE Ratio-9.07
PS Ratio0.00
PB Ratio-19.88
Price to Fair Value-16.80
Price to FCF-26.75
Price to Operating Cash Flow-26.14
PEG Ratio-0.74
Income Statement
In the last 12 months, Xeris Pharmaceuticals had revenue of 203.07M and earned -54.84M in profits. Earnings per share was -0.37.
Revenue203.07M
Gross Profit166.24M
Operating Income-33.65M
Pretax Income-57.10M
Net Income-54.84M
EBITDA-11.30M
Earnings Per Share (EPS)-0.37
Cash Flow
In the last 12 months, operating cash flow was -26.71M and capital expenditures -717.00K, giving a free cash flow of -27.43M billion.
Operating Cash Flow-26.71M
Free Cash Flow-27.43M
Free Cash Flow per Share-0.17
Dividends & Yields
Xeris Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.17
52-Week Price Change106.57%
50-Day Moving Average4.54
200-Day Moving Average3.77
Relative Strength Index (RSI)43.26
Average Volume (3m)2.15M
Important Dates
Xeris Pharmaceuticals upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Xeris Pharmaceuticals as a current ratio of 1.67, with Debt / Equity ratio of -765.06%
Current Ratio1.67
Quick Ratio1.19
Debt to Market Cap0.47
Net Debt to EBITDA-17.68
Interest Coverage Ratio-1.01
Taxes
In the past 12 months, Xeris Pharmaceuticals has paid -2.27M in taxes.
Income Tax-2.27M
Effective Tax Rate0.04
Enterprise Valuation
Xeris Pharmaceuticals EV to EBITDA ratio is -61.69, with an EV/FCF ratio of -18.43.
EV to Sales3.43
EV to EBITDA-61.69
EV to Free Cash Flow-18.43
EV to Operating Cash Flow-18.86
Balance Sheet
Xeris Pharmaceuticals has $58.44M in cash and marketable securities with $268.75M in debt, giving a net cash position of $210.31M billion.
Cash & Marketable Securities$58.44M
Total Debt$268.75M
Net Cash$210.31M
Net Cash Per Share$1.31
Tangible Book Value Per Share-$1.03
Margins
Gross margin is 80.99%, with operating margin of -16.57%, and net profit margin of -27.00%.
Gross Margin80.99%
Operating Margin-16.57%
Pretax Margin-28.12%
Net Profit Margin-27.00%
EBITDA Margin-5.57%
EBIT Margin-13.11%
Analyst Forecast
The average price target for Xeris Pharmaceuticals is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.00
Price Target Upside36.36% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast29.88%
EPS Growth Forecast35.11%